Press Releases

05.15.2018

Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA

05.08.2018

XtalPi Inc. Announces Strategic Research Collaboration with Pfizer Inc. to Develop Artificial Intelligence-Powered Molecular Modeling Technology for Drug Discovery

05.08.2018

New project to enhance nanomedicine development

05.07.2018

Wave Life Sciences Highlights Progress on Hepatic Collaboration with Pfizer

05.01.2018

HUB Announces Collaboration with Pfizer Inc. on Human Gut Organoids for IBD

05.01.2018

Pfizer Reports First-Quarter 2018 Results

04.26.2018

Pfizer Hosts Annual Meeting of Shareholders

04.23.2018

Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years

04.23.2018

Pfizer Provides Update on Proposed Trastuzumab Biosimilar

04.23.2018

MYLOTARG™ Approved In The EU For The Treatment Of Previously Untreated, De Novo, CD33-positive Acute Myeloid Leukemia In Combination With Chemotherapy

04.19.2018

Pfizer Invites Public to Listen to Webcast of April 26 Annual Meeting of Shareholders

04.12.2018

Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy